STAR Compounds Show Potential to Treat GBA1-linked Parkinson’s
Preclinical studies with two compounds, GT-02287 and GT-02329, showed they could reduce the alpha-synuclein aggregates that characterize Parkinson’s and increase glucocerebrosidase protein levels in cell models of Parkinson’s and Gaucher disease.
GT-02287 and GT-02329 are known as STARs, which stands for structurally targeted allosteric regulators. These regulators are designed to help mutated proteins fold correctly and re
...
If you are an active subscriber and the article is not showing, please log out and back in. Free access to articles from 12:00.
Comments
Namibian Sun
No comments have been left on this article